Lean Body Mass-based Levothyroxine Replacement in Young Athyrotic Patients with Differentiated Carcinoma of Thyroid

Overview

Journal Indian J Endocrinol Metab

Specialty Endocrinology

Date 2013 Jun 19

PMID 23776898

Citations 1

Authors

Fatima Begum

Chaudhury M Ahmed

Shahana Afroz

Enamul Kabir

Faridul Alam

Sajal Banerjee

Nazma Zaman

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study was to optimize dose of levothyroxine (LT4) based on lean body mass (LBM) in young athyrotic patients with differentiated carcinoma of thyroid (DCT) which has not been properly addressed in Bangladesh before.

Materials And Methods: SIXTY PATIENTS WITH DCT (AGE, RANGE: 20-39 years) having total thyroidectomy followed by radioiodine ablative therapy (RIT) and 23 euthyroid volunteers were recruited. Clinical, biochemical parameters were obtained from all patients after 2 months of RIT and on LT4 replacement at a dose of 200 μg/day as first follow up visit and also from control subjects. Then 60 patients were divided into two groups consisting of 30 patients each. Patients of Group-I received LT4 replacement based on LBM measured by dual energy X-ray absorptiometry (DXA) and Group-II continued LT4 replacement in conventional dose. Patients of both groups were assessed again for same parameters at 6 to 12 months at the second visit.

Results: Optimized dose of LT4 based on LBM by DXA (131 ±23 μg/day) significantly reduced thyroid hormones and kept thyroid stimulating hormone (TSH) in expected levels in patients of Group-I at the second visit compared to patients of Group-II who continued conventional LT4 dose (200 μg/day). Hyperthyroid symptom scale (HSS) was significantly reduced to 2 ± 1 in patients of Group-I but not in patients of Group-II, HSS, 8 ±1 (P > 0.001).

Conclusion: Optimization of LT4 dose based on LBM can avoid chronic exposure of mild excess of thyroid hormone in young patients with low risk DCT.

Citing Articles

Comparison of the Efficacy of Levothyroxine Suppression Dose Computed Based on Actual Body Weight vs. Lean Body Mass among Differentiated Thyroid Cancer Patients: A Randomized Controlled Trial.

Lu J, Rosales R, Dampil O J ASEAN Fed Endocr Soc. 2021; 34(2):158-163.

PMID: 33442151 PMC: 7784150. DOI: 10.15605/jafes.034.02.06.

References

Klein I, Danzi S . Thyroid disease and the heart. Circulation. 2007; 116(15):1725-35. DOI: 10.1161/CIRCULATIONAHA.106.678326. View

Mazzaferri E, Kloos R . Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001; 86(4):1447-63. DOI: 10.1210/jcem.86.4.7407. View

Andreoli A, Scalzo G, Masala S, Tarantino U, Guglielmi G . Body composition assessment by dual-energy X-ray absorptiometry (DXA). Radiol Med. 2009; 114(2):286-300. DOI: 10.1007/s11547-009-0369-7. View

Ladenson P . Recognition and management of cardiovascular disease related to thyroid dysfunction. Am J Med. 1990; 88(6):638-41. DOI: 10.1016/0002-9343(90)90532-i. View

Pujol P, Daures J, Nsakala N, Baldet L, Bringer J, Jaffiol C . Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab. 1996; 81(12):4318-23. DOI: 10.1210/jcem.81.12.8954034. View

Cooper D, Doherty G, Haugen B, Kloos R, Lee S, Mandel S . Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006; 16(2):109-42. DOI: 10.1089/thy.2006.16.109. View

Lang B, Lo C, Chan W, Lam K, Wan K . Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007; 245(3):366-78. PMC: 1877011. DOI: 10.1097/01.sla.0000250445.92336.2a. View

Botella-Carretero J, Galan J, Caballero C, Sancho J, Escobar-Morreale H . Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr Relat Cancer. 2004; 10(4):601-10. DOI: 10.1677/erc.0.0100601. View

Botella-Carretero J, Gomez-Bueno M, Barrios V, Caballero C, Garcia-Robles R, Sancho J . Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocr Relat Cancer. 2004; 11(2):345-56. DOI: 10.1677/erc.0.0110345. View

10.

Green B, Duffull S . What is the best size descriptor to use for pharmacokinetic studies in the obese?. Br J Clin Pharmacol. 2004; 58(2):119-33. PMC: 1884581. DOI: 10.1111/j.1365-2125.2004.02157.x. View

11.

Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G . Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1993; 77(2):334-8. DOI: 10.1210/jcem.77.2.8345037. View

12.

Daimon M, Watanabe H, Abe Y, Hirata K, Hozumi T, Ishii K . Normal values of echocardiographic parameters in relation to age in a healthy Japanese population: the JAMP study. Circ J. 2008; 72(11):1859-66. DOI: 10.1253/circj.cj-08-0171. View

13.

Santini F, Pinchera A, Marsili A, Ceccarini G, Castagna M, Valeriano R . Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2004; 90(1):124-7. DOI: 10.1210/jc.2004-1306. View

14.

Klein I, Trzepacz P, Roberts M, LEVEY G . Symptom rating scale for assessing hyperthyroidism. Arch Intern Med. 1988; 148(2):387-90. View

15.

Stikkelbroeck N, Oyen W, van der Wilt G, Hermus A, Otten B . Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2003; 88(3):1036-42. DOI: 10.1210/jc.2002-021074. View

16.

Ladenson P . Thyrotoxicosis and the heart: something old and something new. J Clin Endocrinol Metab. 1993; 77(2):332-3. DOI: 10.1210/jcem.77.2.8345036. View

17.

Cooper D, Doherty G, Haugen B, Hauger B, Kloos R, Lee S . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-214. DOI: 10.1089/thy.2009.0110. View

18.

Jana S, Abdel-Dayem H, Young I . Nuclear medicine and thyroid cancer. Eur J Nucl Med. 2000; 26(12):1528-32. DOI: 10.1007/s002590050490. View

19.

Burmeister L, Goumaz M, Mariash C, OPPENHEIMER J . Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 1992; 75(2):344-50. DOI: 10.1210/jcem.75.2.1639933. View

20.

Jonklaas J, Davidson B, Bhagat S, Soldin S . Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA. 2008; 299(7):769-77. DOI: 10.1001/jama.299.7.769. View